Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
psychopraxis. neuropraxis
Erschienen in:

01.09.2016 | Neurologie

„Time is brain“ bei der schubförmigen Multiplen Sklerose

Aktuelle Behandlungskonzepte in der Immuntherapie

verfasst von: Prof. Dr. R. Linker, B.-A. Kallmann, C. Kleinschnitz, P. Rieckmann, M. Mäurer, S. Schwab

Erschienen in: psychopraxis. neuropraxis | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Trotz der diametral unterschiedlichen Zeitskalen, in denen sich die Krankheitsprozesse und -folgen bei der Multiplen Sklerose (MS) und beim ischämischen Schlaganfall manifestieren, zeigen sich konzeptionelle Parallelen zwischen beiden Erkrankungen, die für das Management der MS richtungsweisend sind: Entzündliche Erkrankungsaktivität und konsekutive Neurodegeneration führen zu potenziell irreversibler Gewebeschädigung und damit zu bleibender Behinderung. Dementsprechend sind eine frühzeitige Detektion von Erkrankungsaktivität und eine zeitnahe Intervention bzw. Therapieoptimierung ausschlaggebend für eine Verbesserung der langfristigen Prognose, was sich mit dem in der Akuttherapie des ischämischen Schlaganfalls geprägten Begriff „time is brain“ griffig beschreiben lässt.

Ergebnisse und Diskussion

Bei der MS beinhaltet ein „Time-is-brain“-Konzept den Wert einer frühen Immuntherapie nach Diagnosestellung sowie die Notwendigkeit eines sensitiven strukturierten Monitorings in Verbindung mit frühzeitiger Therapieoptimierung bei Nachweis von Krankheitsaktivität unter Therapie. Das übergeordnete Ziel der Therapie im gesamten Erkrankungsverlauf der MS ist dabei die bestmögliche und anhaltende Kontrolle jeglicher erfassbarer Krankheitsaktivität, insbesondere in der frühen Erkrankungsphase. Im Alltag kann die intersektorale Kooperation in regionalen MS-Netzwerken mit spezialisierten Zentren dazu beitragen, die verfügbaren hochwirksamen Medikamente mit ihren jeweils eigenen Nutzen-Risiko-Profilen optimal einzusetzen und damit die Aussicht auf eine langfristige Stabilisierung der Lebensqualität der MS-Patienten zu erhöhen.
Vorheriger Artikel Dystonie
Nächster Artikel Das Restless-Legs-Syndrom
Literatur
1.
Heesen C, Bohm J, Reich C et al (2008) Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 14:988–991CrossRefPubMed
2.
Feuillet L, Reuter F, Audoin B et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13:124–127CrossRefPubMed
3.
Amato MP, Hakiki B, Goretti B et al (2012) Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 78:309–314CrossRefPubMed
4.
Deloire M, Ruet A, Hamel D et al (2010) Early cognitive impairment in multiple sclerosis predicts disability outcome several years later. Mult Scler 16:581–587CrossRefPubMed
5.
Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285CrossRefPubMed
6.
Kuhlmann T, Lingfeld G, Bitsch A et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202–2212CrossRefPubMed
7.
Kern S, Kuhn M, Ziemssen T (2013) Chronically ill and unemployed? A review on vocational status in multiple sclerosis. Fortschr Neurol Psychiatr 81:95–103CrossRefPubMed
8.
Kobelt G, Berg J, Lindgren P et al (2006) Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77:918–926CrossRefPubMedPubMedCentral
9.
Scalfari A, Neuhaus A, Degenhardt A et al (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133:1914–1929CrossRefPubMedPubMedCentral
10.
Weinshenker BG, Bass B, Rice GP et al (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419–1428CrossRefPubMed
11.
Tremlett H, Yousefi M, Devonshire V et al (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73:1616–1623CrossRefPubMedPubMedCentral
12.
Hirst C, Ingram G, Pearson O et al (2008) Contribution of relapses to disability in multiple sclerosis. J Neurol 255:280–287CrossRefPubMed
13.
Scalfari A, Neuhaus A, Daumer M et al (2013) Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol 70:214–222CrossRefPubMed
14.
Prosperini L, Gallo V, Petsas N et al (2009) One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 16:1202–1209CrossRefPubMed
15.
Fisniku LK, Brex PA, Altmann DR et al (2008) Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131:808–817CrossRefPubMed
16.
Tintore M, Rovira A, Rio J et al (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67:968–972CrossRefPubMed
17.
Lukas C, Knol DL, Sombekke MH et al (2015) Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 86:410–418CrossRefPubMed
18.
Sumowski JF, Rocca MA, Leavitt VM et al (2014) Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology 82:1776–1783CrossRefPubMedPubMedCentral
19.
Fisher E, Rudick RA, Simon JH et al (2002) Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59:1412–1420CrossRefPubMed
20.
Barkhof F, Jong R de, Sfikas N et al (2014) The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler 20:1704–1713CrossRefPubMed
21.
Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839CrossRefPubMed
22.
Fisniku LK, Chard DT, Jackson JS et al (2008) Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 64:247–254CrossRefPubMed
23.
Weinshenker BG, Rice GP, Noseworthy JH et al (1991) The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 114:1045–1056CrossRefPubMed
24.
Edan G, Kappos L, Montalban X et al (2014) Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 85:1183–1189CrossRefPubMed
25.
Hughes S, Spelman T, Trojano M et al (2012) The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. J Neurol Neurosurg Psychiatry 83:305–310CrossRefPubMed
26.
Weinshenker BG, Rice GP, Noseworthy JH et al (1991) The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114:1057–1067CrossRefPubMed
27.
Leray E, Yaouanq J, Le PE et al (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:1900–1913CrossRefPubMedCentral
28.
Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782CrossRefPubMed
29.
Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–616CrossRefPubMed
30.
Leray E, Coustans M, Le PE et al (2013) ‚Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study. Mult Scler 19:458–465CrossRefPubMed
31.
Goldschmidt T, Antel J, Konig FB et al (2009) Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72:1914–1921CrossRefPubMed
32.
Gold R, Hartung HP, Stangel M et al (2012) Therapeutic goals of baseline and escalation therapy for relapsing-remitting multiple sclerosis; Therapeutic goals of baseline and escalation therapy for relapsing-remitting multiple sclerosis. Akt Neurol 39:342–350CrossRef
33.
Havrdova E, Galetta S, Hutchinson M et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254–260CrossRefPubMed
34.
Rotstein DL, Healy BC, Malik MT et al (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72:152–158CrossRefPubMed
35.
Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511CrossRefPubMed
36.
Comi G, De SN, Freedman MS et al (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patient with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11:33–41CrossRefPubMed
37.
Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904CrossRefPubMed
38.
Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389–397CrossRefPubMed
39.
Miller AE, Wolinsky JS, Kappos L et al (2014) Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:977–986CrossRefPubMed
40.
Rudick RA, Lee JC, Cutter GR et al (2010) Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol 67:1329–1335CrossRefPubMed
41.
Goodin DS, Reder AT, Ebers GC et al (2012) Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 78:1315–1322CrossRefPubMedPubMedCentral
42.
Shirani A, Zhao Y, Karim ME et al (2012) Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308:247–256PubMed
43.
Derfuss T, Kappos L (2012) Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA 308:290–291CrossRefPubMed
44.
Prosperini L, Gianni C, Barletta V et al (2012) Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 323:104–112CrossRefPubMed
45.
Cohen JA, Khatri B, Barkhof F et al (2015) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry (im Druck)
46.
Spelman T, Kalincik T, Zhang A et al (2015) Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol 2:373–387CrossRefPubMedPubMedCentral
47.
Rio J, Nos C, Tintore M et al (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344–352CrossRefPubMed
48.
Rio J, Castillo J, Rovira A et al (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15:848–853CrossRefPubMed
49.
Sormani MP, Bruzzi P (2013) MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 12:669–676CrossRefPubMed
50.
Kinkel RP, Simon JH, O’Connor P et al (2014) Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome. Mult Scler Relat Disord 3:712–719CrossRefPubMed
51.
Giovannoni G, Turner B, Gnanapavan S et al (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Dis 4:329–333CrossRef
52.
Freedman MS, Selchen D, Arnold DL et al (2013) Canadian MS Working Group updated recommendations. Can J Neurol Sci 40:307–323CrossRefPubMed
53.
Stangel M, Penner IK, Kallmann BA et al (2015) Development of a multifactorial model to monitor treatment response and disease course in relapsing remitting multiple sclerosis; Multiple Sclerosis Decision Model (MSDM): development of a multifactorial model to monitor treatment response and disease course in relapsing remitting multiple sclerosis. Akt Neurol 40:486–493
54.
Maurer M, Dachsel R, Domke S et al (2011) Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. Eur J Neurol 18:1036–1045CrossRefPubMed
55.
Rio J, Comabella M, Montalban X (2011) Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 24:230–237CrossRefPubMed
Metadaten
Titel
„Time is brain“ bei der schubförmigen Multiplen Sklerose
Aktuelle Behandlungskonzepte in der Immuntherapie
verfasst von
Prof. Dr. R. Linker
B.-A. Kallmann
C. Kleinschnitz
P. Rieckmann
M. Mäurer
S. Schwab
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
psychopraxis. neuropraxis / Ausgabe 4/2016
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI
https://doi.org/10.1007/s00739-016-0332-z

Weitere Artikel der Ausgabe 4/2016

Schubförmige und primär progressive MS. B-Zell-Therapie erweitert therapeutische Optionen

  • aktuell

Fortschritte der letzten Jahrzehnte

  • Brief des Herausgebers

Effekte regionaler Psychosomatiktherapiemodule

  • Open Access
  • Psychiatrie

M. Parkinson: L-Dopa nach wie vor wirksamste Therapie

  • Open Access
  • Neurologie

aktuell

  • aktuell

Dystonie

  • Neurologie